Two months ago, Aprea Therapeutics had about $22.8 million in cash and a runway that extended roughly into Q1 2026. Today? They just closed a $30 million oversubscribed private placement led by Soleus Capital, with Vestal Point and Squadron Capital piling in alongside existing investors.
What changed? The data started working.
APR-1051, Aprea’s selective WEE1 kinase inhibitor, just posted a confirmed partial response in the ongoing Phase 1 ACESOT-1051 trial — greater than 50% tumor shrinkage in a patient with PPP2R1A-mutated endometrial cancer, accompanied by a marked drop in CA-125 levels. That’s now the second confirmed partial response in the study, both in patients with the same mutation.
That pattern matters. WEE1 inhibitors have had a rough history as a drug class. AstraZeneca’s adavosertib showed activity but was plagued by hematological toxicities that limited dosing. What makes APR-1051 different — at least so far — is a distinct molecular structure that Aprea says avoids the blood count problems. No hematological toxicities have been observed to date in the trial. If that holds, it could be a genuine differentiator in a mechanism that pharma hasn’t given up on, just struggled to execute.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
The funding arc tells the story of momentum building in real time. In January, Aprea raised a modest $5.6 million at-the-market — just enough to backfill patients at key dose levels. They also brought on Eugene Kennedy as Chief Medical Advisor, the kind of hire that signals clinical expansion. Then the second partial response hit in February, this one at the 220 mg dose level. By March, they’re raising $30 million oversubscribed.
The biomarker strategy is smart. PPP2R1A mutations create a specific vulnerability to WEE1 inhibition, and Aprea is leaning hard into precision patient selection rather than broad-spectrum oncology. The trial is running at MD Anderson and currently enrolling Cohort 5 at 70mg dosing. Further clinical updates are expected mid-2026.
From near-death to $30 million oversubscribed in about 60 days. That’s what happens when the biology cooperates.
The Biotech Voyager Podcast
Deep dives on the signals shaping early-stage biotech.
